GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (ASX:PYC) » Definitions » EV-to-FCF
中文

PYC Therapeutics (ASX:PYC) EV-to-FCF : -19.54 (As of Apr. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is PYC Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PYC Therapeutics's Enterprise Value is A$391.02 Mil. PYC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-20.01 Mil. Therefore, PYC Therapeutics's EV-to-FCF for today is -19.54.

The historical rank and industry rank for PYC Therapeutics's EV-to-FCF or its related term are showing as below:

ASX:PYC' s EV-to-FCF Range Over the Past 10 Years
Min: -195.76   Med: -29.78   Max: -0.59
Current: -19.77

During the past 13 years, the highest EV-to-FCF of PYC Therapeutics was -0.59. The lowest was -195.76. And the median was -29.78.

ASX:PYC's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.27 vs ASX:PYC: -19.77

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), PYC Therapeutics's stock price is A$0.093. PYC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.006. Therefore, PYC Therapeutics's PE Ratio for today is At Loss.


PYC Therapeutics EV-to-FCF Historical Data

The historical data trend for PYC Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics EV-to-FCF Chart

PYC Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.58 -53.82 -35.83 -8.09 -7.10

PYC Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -8.09 - -7.10 -

Competitive Comparison of PYC Therapeutics's EV-to-FCF

For the Biotechnology subindustry, PYC Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's EV-to-FCF falls into.



PYC Therapeutics EV-to-FCF Calculation

PYC Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=391.024/-20.009
=-19.54

PYC Therapeutics's current Enterprise Value is A$391.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-20.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PYC Therapeutics  (ASX:PYC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PYC Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.093/-0.006
=At Loss

PYC Therapeutics's share price for today is A$0.093.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PYC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.006.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PYC Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PYC Therapeutics (ASX:PYC) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (ASX:PYC) Headlines

No Headlines